This is a weekly update on the latest in longevity. It includes three items in each of these three areas: news, research, and jobs.

Things to know

Here’s what’s going on in longevity.

1. Vivante Health raises $31m Series B

   Vivante Health, a company building gastrointestinal products raised a sizable Series B round last week. Vivante’s product falls under the category of dysbiosis (the aging hallmark that encompasses a breakdown in the microbiome).

2. Longevity Investors Conference kicks off
   Today marks day 1 of The Longevity Investors Conference, an exclusive gathering (the cheapest early bird tickets went for over $4k) of some of the big names in longevity.

3. 2/6 TechCrunch Battlefield Finalists are healthcare companies, with BioticsAI taking top spot
   The journey towards a long life starts with birth. BioticsAI has designed an AI system to analyze prenatal ultrasound images to diagnose malformed fetuses and improve the screening process for OB/GYNs, especially in less-developed areas.

Research

A short review of some papers and reports, both recents and classics, related to aging.

1. International Diabetes Foundation Atlas
   Type II diabetes is the result of deregulated nutrient sensing by various across the body. This report from the International Diabetes Foundation to be a fascinating look at the scale of the problem (587m people, $966b in related costs). Plus, diabetes leads to other diseases like atherosclerosis.

2. Hayflick limit
   This paper published in 1961 upset the theory that cells were immortal, establishing an ~40 division limit before cells would become senescent.

3. Epigenetic clock theory of aging
   When asking someone how old they are, usually they’ll tell you their chronological age. In the future, people may start telling you their biological age. This paper proposes a method, based on epigenetic tags, to measure biological age.

Get involved

A breakdown of the latest jobs at companies in or around the longevity space.

Altos Labs
Altos is a cellular reprogramming company, meaning they work on the epigenetic hallmark of aging. They are also one of the most well-funded biotech companies, raising north of $3b.

1. Imaging and Bioinformatics Machine Learning Scientist
   San Fransisco — $187k-$378k
   PhD (CS or biomed)
   Experience in Python, C++, Scala, Julia, etc.

2. Scientist/Senior Scientist, Molecular and Cell Biology
   San Fransisco — $121k-$253k
   PhD (life sciences)
   Part of Altos’ academic arm

3. Director/Senior Director Intellectual Property
   San Diego — $319k-$462k
   Science + legal role - need both
   Two identical positions (San Francisco & Cambridge, UK)

Cheers,